tetano
Editor, Senior Moderator
Sci Rep. 2015 Mar 2;5:8672. doi: 10.1038/srep08672.
[h=1]A cell-based screening system for anti-influenza A virus agents.[/h] Wong WY[SUP]1[/SUP], Loh SW[SUP]1[/SUP], Ng WL[SUP]1[/SUP], Tan MC[SUP]1[/SUP], Yeo KS[SUP]1[/SUP], Looi CY[SUP]2[/SUP], Maah MJ[SUP]3[/SUP], Ea CK[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Emerging of drug resistant influenza A virus (IAV) has been a big challenge for anti-IAV therapy. In this study, we describe a relatively easy and safe cell-based screening system for anti-IAV replication inhibitors using a non-replicative strain of IAV. A nickel (II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone (NiPT5) was recently found to exhibit anti-inflammatory activity in vivo and in vitro. NiPT5 impedes the signaling cascades that lead to the activation of NF-κB in response to different stimuli, such as LPS and TNFα. Using our cell-based screening system, we report that pretreating cells with NiPT5 protects cells from influenza A virus (IAV) and vesicular stomatitis virus (VSV) infection. Furthermore, NiPT5 inhibits replication of IAV by inhibiting transcription and translation of vRNAs of IAV. Additionally, NiPT5 reduces IAV-induced type I interferon response and cytokines production. Moreover, NiPT5 prevents activation of NF-κB, and IRF3 in response to IAV infection. These results demonstrate that NiPT5 is a potent antiviral agent that inhibits the early phase of IAV replication.
PMID: 25728279 [PubMed - in process]
[h=1]A cell-based screening system for anti-influenza A virus agents.[/h] Wong WY[SUP]1[/SUP], Loh SW[SUP]1[/SUP], Ng WL[SUP]1[/SUP], Tan MC[SUP]1[/SUP], Yeo KS[SUP]1[/SUP], Looi CY[SUP]2[/SUP], Maah MJ[SUP]3[/SUP], Ea CK[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Emerging of drug resistant influenza A virus (IAV) has been a big challenge for anti-IAV therapy. In this study, we describe a relatively easy and safe cell-based screening system for anti-IAV replication inhibitors using a non-replicative strain of IAV. A nickel (II) complex of polyhydroxybenzaldehyde N4-thiosemicarbazone (NiPT5) was recently found to exhibit anti-inflammatory activity in vivo and in vitro. NiPT5 impedes the signaling cascades that lead to the activation of NF-κB in response to different stimuli, such as LPS and TNFα. Using our cell-based screening system, we report that pretreating cells with NiPT5 protects cells from influenza A virus (IAV) and vesicular stomatitis virus (VSV) infection. Furthermore, NiPT5 inhibits replication of IAV by inhibiting transcription and translation of vRNAs of IAV. Additionally, NiPT5 reduces IAV-induced type I interferon response and cytokines production. Moreover, NiPT5 prevents activation of NF-κB, and IRF3 in response to IAV infection. These results demonstrate that NiPT5 is a potent antiviral agent that inhibits the early phase of IAV replication.
PMID: 25728279 [PubMed - in process]